Item Type | Name |
Academic Article
|
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
|
Academic Article
|
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
|
Academic Article
|
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
|
Academic Article
|
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
|
Academic Article
|
Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
|
Academic Article
|
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
|
Academic Article
|
Chimeric T-cell receptors for the targeting of cancer cells.
|
Academic Article
|
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
|
Academic Article
|
Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis.
|
Academic Article
|
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.
|
Academic Article
|
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.
|
Academic Article
|
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
|
Academic Article
|
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
|
Academic Article
|
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
|
Academic Article
|
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
|
Academic Article
|
Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
|
Academic Article
|
T cell receptors and cancer: gain gives pain.
|
Academic Article
|
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.
|
Academic Article
|
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
|
Academic Article
|
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
|
Academic Article
|
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
|
Academic Article
|
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.
|
Academic Article
|
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes.
|
Academic Article
|
Antigen-induced regulatory T cells.
|
Academic Article
|
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
|
Academic Article
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
Academic Article
|
Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.
|
Academic Article
|
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".
|
Academic Article
|
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
|
Academic Article
|
Adoptive T cell therapy of cancer.
|
Academic Article
|
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
|
Concept
|
Antigen Presentation
|
Concept
|
Receptors, Antigen
|
Concept
|
Receptors, Antigen, T-Cell, alpha-beta
|
Concept
|
Receptors, Antigen, T-Cell
|
Concept
|
T-Cell Antigen Receptor Specificity
|
Concept
|
Antigen-Antibody Reactions
|
Concept
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
|
Concept
|
Antigen-Presenting Cells
|
Concept
|
B7-1 Antigen
|
Concept
|
Ki-1 Antigen
|
Concept
|
B7-2 Antigen
|
Concept
|
HLA-A2 Antigen
|
Academic Article
|
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
|
Academic Article
|
CAR T cells for acute myeloid leukemia: the LeY of the land.
|
Academic Article
|
Design and development of therapies using chimeric antigen receptor-expressing T cells.
|
Academic Article
|
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.
|
Academic Article
|
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
|
Academic Article
|
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.
|
Academic Article
|
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
|
Academic Article
|
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
|
Academic Article
|
CAR-T Cell Therapy for Lymphoma.
|
Academic Article
|
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains.
|
Academic Article
|
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape.
|
Academic Article
|
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.
|
Academic Article
|
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
|
Academic Article
|
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
|
Academic Article
|
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
|
Academic Article
|
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
|
Academic Article
|
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
|
Academic Article
|
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
|
Academic Article
|
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
|
Academic Article
|
Next Steps in the CAR Journey of a Thousand Miles.
|
Academic Article
|
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
|
Academic Article
|
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
|
Academic Article
|
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.
|
Academic Article
|
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
|
Academic Article
|
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
|
Academic Article
|
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
|
Academic Article
|
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
|
Grant
|
ACTIVITY OF LYMPHOTACTIN IN CHILDHOOD MALIGNANCY
|
Grant
|
Haploidentical Allogeneic Transplantation
|
Academic Article
|
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
|
Academic Article
|
Adoptive Cell Therapy: ACT-Up or ACT-Out?
|
Academic Article
|
Chimeric Antigen Receptors for T-Cell Malignancies.
|
Concept
|
MART-1 Antigen
|
Concept
|
B7-H1 Antigen
|
Academic Article
|
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape.
|
Academic Article
|
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
|
Academic Article
|
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
|
Academic Article
|
Engineered off-the-shelf therapeutic T cells resist host immune rejection.
|
Academic Article
|
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
|
Academic Article
|
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
|
Academic Article
|
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.
|
Academic Article
|
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8a?-engineered human CD4+ T cells.
|
Academic Article
|
Transgenic CD8a? co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells.
|
Academic Article
|
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
|
Academic Article
|
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
|
Academic Article
|
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
|
Academic Article
|
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape.
|
Academic Article
|
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
|
Academic Article
|
Targeting glycans for CAR therapy: The advent of sweet CARs.
|
Academic Article
|
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies.
|
Academic Article
|
Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
|
Academic Article
|
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
|